Table 5.
Association of BMI and WC with Clinicophatological Variable among Postmenopausal Breast Cancer. Brazil, 2017
| ER Status | PR Status | HeR-2 Status | TN | |||||
|---|---|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | Negative | Positive | Yes | No | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Prediagnosis BMI (kg/m2) | ||||||||
| <30 | 13 (31.7) | 28 (68.3) | 15 (37.5) | 25 (62.5) | 9 (28.1) | 23 (71.9) | 6 (18.8) | 26 (81.3) |
| ≥30 | 1 (4.8) | 20 (95.2) | 3 (14.3) | 18 (85.7) | 6 (35.3) | 11 (64.7) | 0 (0.0) | 17 (100.0) |
| p value | 0.01* | 0.05* | 0.60 | 0.06* | ||||
| Current BMI (kg/m2) | ||||||||
| <30 | 6 (15.4) | 33 (84.6) | 10 (26.3) | 28 (73.7) | 9 (31.0) | 20 (69.0) | 27 (93.1) | 2 (6.9) |
| ≥30 | 8 (34,8) | 15 (65.2) | 8 (34.8) | 15 (65.2) | 6 (30.0) | 14 (70.0) | 16 (80.0) | 4 (20.0) |
| p value | 0.07 | 0.48 | 0.93 | 0.17* | ||||
| BMI at age 20 years (kg/m2) | ||||||||
| <30 | 13 (21.3) | 48 (78.7) | 17 (28.3) | 43 (71.7) | 15 (31.3) | 33 (68.8) | 6 (12.5) | 42 (87.5) |
| ≥30 | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |
| p value | 0.22* | 0.29* | 0.69* | 0.87* | ||||
| Waist circumference (cm) | ||||||||
| <80 | 1 (20.0) | 4 (80.0) | 1 (20.0) | 4 (80.0) | 2 (40.0) | 3 (60.0) | 1 (20.0) | 4 (80.0) |
| ≥80 | 13 (22.8) | 44 (77.2) | 17 (30.4) | 39 (69.6) | 13 (29.5) | 31 (70.5) | 5 (11.4) | 39 (88.6) |
| p value | 0.68* | 0.53* | 0.48* | 0.49* | ||||
ER, estrogen receptor; PR, progesterone receptor; HER-2, Human Epidermal growth factor Receptor 2; TN, triple-negative;
*
Fisher´s exact test